Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers

Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With... ORIGINAL ARTICLE Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers SoJeong Yi, MS, Tae-Eun Kim, MD, Seo Hyun Yoon, PhD, Joo-Youn Cho, PhD, Sang-Goo Shin, MD, PhD, In-Jin Jang, MD, PhD, and Kyung-Sang Yu, MD, PhD INTRODUCTION Aim: Fimasartan (BR-A-657) is a new angiotensin II receptor an- Fimasartan (BR-A-657, Boryung Pharmaceutical Co. tagonist used as antihypertensive agent. The objective of this study Ltd. Seoul, South Korea) is a new nonpeptide angiotensin II was to investigate the effect of the coadministration of fimasartan and receptor antagonist with a selective AT1 receptor–blocking amlodipine on the steady-state pharmacokinetics of each drug. effect, which was approved for the treatment of hypertension by the Korean Food and Drug Administration in 2010. Methods: This study comprised 2 separate parts, A and B; each was In therapeutic exploratory clinical studies of mild to a multiple-dose, open-label, 2-period crossover study in healthy male moderate hypertensive patients, fimasartan ($60 mg) signif- volunteers. In part A, 20 subjects were administered 120 mg of icantly decreased blood pressure after an 8-week treatment fimasartan alone in period I and fimasartan with 10 mg of amlodipine compared with the placebo group with sufficient safety and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Cardiovascular Pharmacology Wolters Kluwer Health

Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers

Journal of Cardiovascular Pharmacology , Volume 57 (6) – Jun 1, 2011

Loading next page...
 
/lp/wolters-kluwer-health/pharmacokinetic-interaction-of-fimasartan-a-new-angiotensin-ii-CA2XeOpDkz

References (23)

Copyright
Copyright © 2011 by Lippincott Williams & Wilkins
ISSN
0160-2446
eISSN
1533-4023
DOI
10.1097/FJC.0b013e31821795d0
pmid
21394036
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Pharmacokinetic Interaction of Fimasartan, a New Angiotensin II Receptor Antagonist, With Amlodipine in Healthy Volunteers SoJeong Yi, MS, Tae-Eun Kim, MD, Seo Hyun Yoon, PhD, Joo-Youn Cho, PhD, Sang-Goo Shin, MD, PhD, In-Jin Jang, MD, PhD, and Kyung-Sang Yu, MD, PhD INTRODUCTION Aim: Fimasartan (BR-A-657) is a new angiotensin II receptor an- Fimasartan (BR-A-657, Boryung Pharmaceutical Co. tagonist used as antihypertensive agent. The objective of this study Ltd. Seoul, South Korea) is a new nonpeptide angiotensin II was to investigate the effect of the coadministration of fimasartan and receptor antagonist with a selective AT1 receptor–blocking amlodipine on the steady-state pharmacokinetics of each drug. effect, which was approved for the treatment of hypertension by the Korean Food and Drug Administration in 2010. Methods: This study comprised 2 separate parts, A and B; each was In therapeutic exploratory clinical studies of mild to a multiple-dose, open-label, 2-period crossover study in healthy male moderate hypertensive patients, fimasartan ($60 mg) signif- volunteers. In part A, 20 subjects were administered 120 mg of icantly decreased blood pressure after an 8-week treatment fimasartan alone in period I and fimasartan with 10 mg of amlodipine compared with the placebo group with sufficient safety and

Journal

Journal of Cardiovascular PharmacologyWolters Kluwer Health

Published: Jun 1, 2011

There are no references for this article.